Planned 6,349-share stock sale by Mineralys Therapeutics (NASDAQ: MLYS)

Rhea-AI Filing Summary

Selling shareholder David Rodman plans to sell 6,349 shares of Mineralys Therapeutics, Inc. common stock through Merrill Lynch, with an aggregate market value of about $168,954.55 and a proposed sale date of 07/15/2026. These shares were acquired via an exercise of employee stock options on 07/14/2025 for cash. The disclosure also records multiple prior Mineralys common stock sales by Rodman between April and July 2026, each with specified share counts and dollar values.

Key Figures

Shares proposed for sale: 6349 shares Aggregate market value of proposed sale: 168954.55 Proposed sale date: 07/15/2026 +5 more

8 metrics

Shares proposed for sale 6349 shares Securities To Be Sold section for Mineralys Therapeutics common stock

Aggregate market value of proposed sale 168954.55 Value associated with planned sale of 6349 shares

Proposed sale date 07/15/2026 Date for the planned sale of common stock through Merrill Lynch

Shares acquired via option exercise 6349 shares Exercise of employee stock options on 07/14/2025

Shares sold on 05/13/2026 14056 shares Common Stock sale by David Rodman on 05/13/2026

Value of 05/13/2026 sale 401789.92 Dollar amount for 14056-share sale on 05/13/2026

Shares sold on 07/13/2026 14058 shares Common Stock sale by David Rodman on 07/13/2026

Value of 07/13/2026 sale 387716.51 Dollar amount for 14058-share sale on 07/13/2026

Key Terms

Exercise of employee stock options, Securities To Be Sold, Securities Sold During The Past 3 Months

3 terms

Exercise of employee stock options financial

"Common Stock | 07/14/2025 | Exercise of employee stock options | Mineralys"

Securities To Be Sold regulatory

"144: Securities To Be Sold Common Stock | Merrill Lynch | 6349"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months David Rodman | Common Stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/15/2026 - 04:14 PM Accepted by SEC EDGAR 07/15/2026 - 04:13 PM Learn about SEC filing dates

FAQ

What stock is being sold in Mineralys Therapeutics (MLYS)'s Form 144 notice?

The notice covers 6,349 shares of Mineralys Therapeutics, Inc. common stock. These shares are to be sold through Merrill Lynch and have an aggregate market value of approximately $168,954.55 based on the figures disclosed.

Who is the selling security holder in Mineralys Therapeutics (MLYS)'s Form 144 and which broker is used?

The selling security holder is David Rodman. The broker handling the proposed sale of Mineralys Therapeutics common stock is Merrill Lynch, located at 225 Liberty St, Floor 37, New York, NY 10281.

What is the aggregate market value of Mineralys Therapeutics (MLYS) shares proposed for sale?

The planned sale of 6,349 shares of Mineralys Therapeutics common stock has an aggregate market value of $168,954.55. This value is tied to the proposed transaction disclosed for execution on 07/15/2026.

When is the proposed sale date for the Mineralys Therapeutics (MLYS) shares in this Form 144?

The proposed sale date for the 6,349 shares of Mineralys Therapeutics common stock is 07/15/2026. This date appears in the section describing the securities to be sold through Merrill Lynch on NASDAQ.

How were the Mineralys Therapeutics (MLYS) shares in this Form 144 acquired?

The 6,349 Mineralys Therapeutics shares were acquired through an exercise of employee stock options on 07/14/2025. The consideration for this acquisition was paid in cash, as indicated in the transaction details.

What prior Mineralys Therapeutics (MLYS) stock sales by David Rodman are disclosed for the past 3 months?

The disclosure lists several sales, including 14,056 shares for $401,789.92 on 05/13/2026 and 14,058 shares for $387,716.51 on 07/13/2026, along with multiple other smaller transactions between April and June 2026.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	6349	168954.55	82498101	07/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/14/2025	Exercise of employee stock options	Mineralys Therapeutics, Inc.			6349	07/14/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	04/15/2026	6348	175585.68
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	04/17/2026	416	13033.28
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/11/2026	2171	64500.41
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/12/2026	6348	186348.35
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/13/2026	14056	401789.92
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/18/2026	417	11488.35
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/10/2026	2170	54250.00
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/12/2026	6349	151901.37
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/15/2026	9890	235487.24
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/17/2026	4584	114600.00
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/09/2026	2171	65781.30
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/13/2026	14058	387716.51

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)